Vericel (NasdaqGM:VCEL) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsEric Burns - VP of Finance and Investor RelationsJeffrey Cohen - Managing Director and Director of Equity ResearchJoe Mara - CFOJosh Jennings - Managing DirectorNick Colangelo - President and CEOConference Call ParticipantsMason Carrico - Research AnalystRyan Zimmerman - Managing Director and Medical Technology AnalystSwayampakula Ramakanth - Managing Director and Senior Healthcare AnalystNone - AnalystNone - Ana ...

Anika Therapeutics (NasdaqGS:ANIK) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker4Good morning, ladies and gentlemen, and welcome to Anika's fourth quarter and year-end earnings conference call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Thursday, February 26, 2026. I would now ...

ACADIA Pharmaceuticals (NasdaqGS:ACAD) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker11Thank you for standing by. My name is J.L., and I will be your conference operator today. At this time, I would like to welcome everyone to the ACADIA Pharmaceuticals Inc. fourth quarter earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press s ...

Core Insights - United Therapeutics Corporation reported fourth-quarter results that exceeded earnings expectations but fell short on revenue, leading to a more than 9% increase in shares intra-day [1] Financial Performance - Adjusted earnings per share for the fourth quarter were $7.70, surpassing the consensus estimate of $7.10 by $0.60 [1] - Revenue for the fourth quarter totaled $790.2 million, below expectations of $815.24 million, but represented a 7% increase from $735.9 million in the prior-year quarter [2] - Full-year 2025 revenue reached a record $3.18 billion, up 11% from 2024 [2] Product Revenue Breakdown - Total Tyvaso revenue grew 12% to $464.3 million in the fourth quarter, driven by Tyvaso DPI, which increased 24% to $338.6 million [3] - Growth in Tyvaso revenue was attributed to higher quantities sold due to continued patient expansion and increased commercial utilization linked to Medicare Part D redesign under the Inflation Reduction Act [3] - Orenitram revenue rose 12% to $121.2 million [3] Net Income and Future Outlook - Net income for the quarter reached $364.3 million, or $7.70 per diluted share, compared to $301.3 million, or $6.19 per diluted share, in the fourth quarter of 2024 [4] - For full-year 2025, net income totaled $1.33 billion, up from $1.20 billion in 2024 [4] - Management indicated that the ADVANCE OUTCOMES and TETON-1 clinical programs are expected to deliver pivotal data that could expand treatment options [4]

Axon Enterprise Inc (NASDAQ:AXON) reported better-than-expected fourth-quarter financial results and issued FY26 sales guidance above estimates on Tuesday.Axon posted fourth-quarter revenue of $796.72 million, beating analyst estimates of $755.40 million. The company reported fourth-quarter adjusted earnings of $2.15 per share, beating estimates of $1.60 per share, according to Benzinga Pro."Our momentum is accelerating as we enter 2026, supported by disciplined investment, strong product market fit and dee ...

BWS Financial raised the firm’s price target on Adeia (ADEA) to $30 from $24 and keeps a Buy rating on the shares. Adeia’s Q4 results were ahead of expectations and the company has begun 2026 with licensing deals with Microsoft (MSFT) and an undisclosed semiconductor company, giving Adeia a pathway to grow revenue and free cash flow beyond 2025 levels, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try ...

Steven Madden (NasdaqGS:SHOO) Q4 2025 Earnings call February 25, 2026 08:30 AM ET Company ParticipantsAubrey Tianello - Equity ResearchDana Telsey - CEO and Chief Research OfficerDanielle McCoy - VP of Corporate Development and Investor RelationsEdward Rosenfeld - Chairman and CEOMarni Shapiro - Founding PartnerPaul Lejuez - Managing Director and Head of Consumer Discretionary ResearchZine Mazouzi - CFO and EVP of OperationsConference Call ParticipantsAnna Andreeva - Managing Director and Senior Research An ...

Inogen, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Transformation and Performance Drivers Achieved a strategic pivot from a single-product oxygen company to a diversified respiratory platform spanning oxygen, sleep therapy, airway clearance, and digital health. Delivered first full year of positive adjusted EBITDA since 2021, driven by disciplined cost management and operational leverage from a 4% revenue increase. Attributed 20% unit volume growth to the ongoing market conversion from trad ...

The company also reported improved profitability in the quarter. Gundermann said operating income margin was 14.8% and adjusted EBITDA was 19% , which he called post-pandemic records. Astronics generated $27.6 million in cash from operations in the quarter and ended the period with $231 million of available liquidity after completing a planned transition from an asset-based lending facility to a cash flow-based revolving credit facility.Chairman, President and CEO Peter Gundermann said fourth-quarter revenu ...

Supernus Pharmaceuticals (NasdaqGM:SUPN) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsJack A. Khattar - President and CEOPeter Vozzo - Managing DirectorTim Dec - CFONone - Company RepresentativeConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystJon Cox - AnalystKristen Kluska - AnalystPavan Patel - Biopharma Equity Research AnalystStacy Ku - AnalystOperatorGood afternoon. Welcome to Supernus Pharmaceuticals for the quarter and full year 2025 ...